COMMUNIQUÉS West-GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 29,416 shares of [...]
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public [...]
Erasca Announces Proposed Public Offering of $150 Million of Common Stock
20/01/2026
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
BioAge Announces Proposed Public Offering
20/01/2026
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic [...]
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
20/01/2026
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“ Anteris ” or the “ Company ”) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to [...]
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
20/01/2026
Vancouver, Canada, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel [...]
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
20/01/2026
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight [...]
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
20/01/2026
LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing [...]
Protext Mobility, Inc. (OTC: TXTM) is thrilled to share a transformative update, advancing uplisting readiness with a preliminary Deloitte engagement
20/01/2026
FORT LAUDERDALE, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM) (“Protext” “TXTM” or the “Company”) is thrilled to share a transformative update that underscores its strategic execution, [...]
Gold medal winner at SIVAL, Amoéba displays its ambitions for its biocontrol solution
20/01/2026
Chassieu, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Chassieu (France), 20 January 2026 – 6:00 pm - Amoéba (FR0011051598 - ALMIB) , industrial greentech specialised in the development of natural microbiological solutions based [...]
Bacterial Mechanism That Could Help Prevent and Treat Lyme Arthritis Identified by New Bay Area Lyme Foundation–Supported Study
20/01/2026
Research published in PLOS Pathogens highlights a cell wall–driven trigger of joint inflammation, pointing to new ways to target Lyme arthritis PORTOLA VALLEY, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Bay Area Lyme [...]
TOMI Environmental Solutions Secures UK CES contract integrating SteraMist iHP into Total Clean Air's Modular Cleanroom Platform
20/01/2026
FREDERICK, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced the sale of a Custom [...]
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
20/01/2026
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process Company expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO, Jan. 20, 2026 (GLOBE [...]
New National Report: Nurse-Led Coordination Strengthens Patient Access, Reduces Delays and Improves Throughput Across U.S. Health Systems
20/01/2026
Survey finds nurse-first models help avoid three-quarters of unnecessary ED visits, are rated highly effective for reducing readmissions, and enhance patient outcomes through streamlined coordination Cincinnati, Jan. 20 [...]
First-of-its-kind Trojan Horse Cancer Treatment Approved for Clinical Trials
20/01/2026
Peptinovo Biopharma’s Targeted Cancer Drug Platform Moves to Human Trials in Australia ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering [...]
Adaptin Bio Advances Novel Brain Cancer Treatment Candidate Towards Phase 1 Glioblastoma Clinical Trial
20/01/2026
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to begin APTN-101, the Company’s Brain Bispecific T cell Engager (BRiTE), yields [...]
Comfort Keepers Ireland Highlights Urgent Need for Scaling Safe, Regulated Home Support
20/01/2026
Report Emphasises the Importance of Home Support in Alleviating Hospital Pressures and Supporting Aging Population Dublin, Ireland, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Comfort Keepers Ireland , a leading homecare provider [...]
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
20/01/2026
High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine in NSCLC advances [...]
Rentschler Biopharma Announces Executive Board Changes and Next Phase of Corporate Strategy
20/01/2026
Company implements next growth stage following successful strategic and operational development Uwe Buecheler, PhD, Vice Chairman of the Supervisory Board, appointed interim CEO LAUPHEIM, Germany and MILFORD, Mass., Jan [...]

Pages